{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tao Y"],"funding":["Chief Scientist Office"],"pagination":["601"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11852610"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(4)"],"pubmed_abstract":["<b>Background:</b> Better prognostic biomarkers are needed in older adults with cancer. There are established links between N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) and sarcopenia, and sarcopenia is associated with poorer cancer survival. However, there are limited data regarding baseline NT-proBNP as a biomarker of cancer outcome. The GO2 trial recruited older and/or frail United Kingdom (UK) patients with advanced gastroesophageal cancer and investigated the role of chemotherapy dose de-escalation. Using the GO2 database, we sought to investigate the prognostic role of NT-proBNP as well as the interaction between NT-proBNP and frailty. <b>Methods:</b> This was a post-hoc analysis of a completed clinical trial. Frailty measures included ECOG performance status (PS) and GO2 fr"],"journal":["Cancers"],"pubmed_title":["N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)-A Prognostic Biomarker in Older and/or Frail Adults with Advanced Gastroesophageal Cancer: A Post Hoc Analysis of the GO2 Clinical Trial."],"pmcid":["PMC11852610"],"funding_grant_id":["CAF20/01"],"pubmed_authors":["Hall PS","Petty RD","Baxter MA","Tao Y","Lang CC"],"additional_accession":[]},"is_claimable":false,"name":"N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)-A Prognostic Biomarker in Older and/or Frail Adults with Advanced Gastroesophageal Cancer: A Post Hoc Analysis of the GO2 Clinical Trial.","description":"<b>Background:</b> Better prognostic biomarkers are needed in older adults with cancer. There are established links between N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) and sarcopenia, and sarcopenia is associated with poorer cancer survival. However, there are limited data regarding baseline NT-proBNP as a biomarker of cancer outcome. The GO2 trial recruited older and/or frail United Kingdom (UK) patients with advanced gastroesophageal cancer and investigated the role of chemotherapy dose de-escalation. Using the GO2 database, we sought to investigate the prognostic role of NT-proBNP as well as the interaction between NT-proBNP and frailty. <b>Methods:</b> This was a post-hoc analysis of a completed clinical trial. Frailty measures included ECOG performance status (PS) and GO2 fr","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-22T20:06:32.373Z","creation":"2025-04-06T03:03:55.63Z"},"accession":"S-EPMC11852610","cross_references":{"pubmed":["40002196"],"doi":["10.3390/cancers17040601"]}}